Navigation Links
Drug stabilizes cancer growth

A experimental drug stopped the progression of cancer in 7 out of 10 patients while causing minimal side effects. The drug phenoxodiol was given to patients with a variety of cancers that failed// standard chemotherapy drugs in a study done by the Ohio-based Cleveland Clinic.

Phenoxodiol belongs to a relatively new class of drugs known as signal transduction inhibitors, all designed to switch off certain cancer processes. Phenoxodiol was discovered by Novogen Ltd., Marshall Edwards' Australian parent company.

Phenoxodiol appears to work by inhibiting an enzyme that is vital for cancer growth. With the drug interfering with this enzyme rather than directly attacking cells, normal healthy cells are left untouched, reducing side effects. However, patients in the study did experience some nausea and fatigue.

"I am encouraged that this drug appears to have so few side effects," said Dr. Ronald Bukowski, director of experimental therapies at the Cleveland Clinic's Taussig Cancer Center. "We hope to get to the point where we can give patients enough medicine for it to be effective.
'"/>




Page: 1

Related medicine news :

1. Vitamin B12 can help in detecting cancers
2. Want skin cancer? Please have a cigarette
3. New hope for cancer victims – will vaccine cure the deadly bug
4. Clintons new problem - Is the outgoing American president suffering from skin cancer?
5. Are cancer patients being taken for a ride?
6. Breast cancer treatment to be determined by gene test
7. Ductal lavage may detect early breast cancer
8. Beware of the oral patch! It could be cancer!!!
9. New drug helps boost cancer treatment
10. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
11. Lose stomach for Life....Preventive removal of stomach saves the risk of cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 /PRNewswire/ ... health and big data solutions, today announced that its MyDario product is ... your local TV listings for when The Dr. Oz Show airs in ... The nine-time ... month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: